Physician profile
Samir Patel
NPI 1174759419
$318.46
in general payments reported to CMS, 2019-2025
11 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.34 · 2020: $31.03 · 2021: $52.82 · 2022: $76.22 · 2023: $19.00 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $65.17 | 2025 | |
| Genzyme Corporation | $60.88 | 2019-2025 | |
| Cti Biopharma Corp. | $47.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.84 | 2021 | |
| Emd Serono, INC. | $28.42 | 2022 | |
| Tactile Systems Technology INC | $19.00 | 2023 | Flexitouch Plus, Entre Plus |
| Seagen INC. | $18.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.34 | 2019 | |
| Amgen INC. | $13.03 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.06 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.